Prosecution Insights
Last updated: November 04, 2026
Application No. 18/602,140

MULTIPLE AMPLIFICATION CYCLE DETECTION

Non-Final OA §103§112
Filed
Mar 12, 2024
Priority
Sep 10, 2012 — provisional 61/699,103 +4 more
Examiner
HORLICK, KENNETH R
Art Unit
1681
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Biofire Diagnostics LLC
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
832 granted / 1053 resolved
+19.0% vs TC avg
Strong +15% interview lift
Without
With
+15.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
28 currently pending
Career history
1088
Total Applications
across all art units

Statute-Specific Performance

§101
7.9%
-32.1% vs TC avg
§103
28.3%
-11.7% vs TC avg
§102
9.9%
-30.1% vs TC avg
§112
35.0%
-5.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1053 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status 1. The present application is being examined under the pre-AIA first to invent provisions. OBJECTIONS 2. The specification is objected to because of the following informality: the continuation information must be updated to indicate the current status of the parent applications. 3. Claims 14-20 are objected to because of the following informality in independent claim 14: ‘pf’ instead of ‘of’ in line 3. Correction is required. NON-PRIOR ART REJECTIONS 4. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 7-8 and 20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A) Claim 7 is indefinite because ‘the melt curve’ lacks proper antecedent basis. Correction is required. B) Claims 8 and 20 are indefinite because it cannot be determined what is encompassed by the language ‘nearly at most every fifth amplification cycle’. Clarification is required. 5. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-20 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. These claims recite the language ‘melt signature’, ‘denaturation phase’, ‘fluorescent signal decay’, ‘temperature window’, ‘melt characteristic’, and ‘slope’. The Office finds no support for this language in the specification, so the claims comprise new matter. If this rejection is traversed, it is requested that support in the specification be pointed to with particularity, as in page, line, or paragraph numbers, and that support be pointed to for the further limitations of the dependent claims. PRIOR ART REJECTION 6. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. 7. The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made. 8. The factual inquiries for establishing a background for determining obviousness under pre-AIA 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 9. This application currently names joint inventors. In considering patentability of the claims under pre-AIA 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of pre-AIA 35 U.S.C. 103(c) and potential pre-AIA 35 U.S.C. 102(e), (f) or (g) prior art under pre-AIA 35 U.S.C. 103(a). 10. Claims 1-20 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Ririe et al. (US 2010/0056383). Regarding independent claims 1, 9, and 14, Ririe discloses a method comprising providing a container with wells comprising amplification primers and dsDNA binding dye, simultaneously amplifying nucleic acids in the wells, monitoring a fluorescence signal, observing a melt signature for the wells, repeating the previous two steps, and determining Cp for amplification. See paragraphs 0006-0012, 0056-0066, 0115-0126, and 0169-0177. While the disclosure of Ririe covers all of the limitations of the independent claims in separate portions of the reference, Ririe does not disclose a single embodiment anticipating the claims which includes melt curve analysis. However, the use of melt curve analysis and Cp determination in the context of controls is disclosed in paragraph 0172, suggesting that melt curve analysis and Cp determination be applied in the other embodiments disclosed by Ririe. It would have been prima facie obvious to one of ordinary skill in the art at the time the application was filed to carry out the claimed methods. Regarding dependent claims 2-8, 10-13, and 15-20, the further limitations all merely involve straightforward, logical scientific reasoning or routine optimization of known-important reaction parameters related to melt analysis and Cp determination, which as well established in U.S. patent practice does not support unobviousness (M.P.E.P. 2144.05). CONCLUSION 11. No claims are free of the prior art. 12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KENNETH R HORLICK whose telephone number is (571)272-0784. The examiner can normally be reached Mon. - Thurs. 8:30 - 6:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gary Benzion can be reached at 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. 08/27/26 /KENNETH R HORLICK/ Primary Examiner, Art Unit 1681
Read full office action

Prosecution Timeline

Mar 12, 2024
Application Filed
Sep 01, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781273
PCR DETECTION OF SMALL FRAGMENTS OF A KNOWN NUCLEIC ACID TARGET
3y 3m to grant Granted Nov 03, 2026
Patent 12747466
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH EXTRACELLULAR VESICLES
3y 4m to grant Granted Sep 29, 2026
Patent 12735751
SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATION
11m to grant Granted Sep 15, 2026
Patent 12729401
CHIMERIC AMPLICON ARRAY SEQUENCING
3y 9m to grant Granted Sep 08, 2026
Patent 12729402
METHODS AND SYSTEMS FOR PROCESSING POLYNUCLEOTIDES
1y 5m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
94%
With Interview (+15.3%)
2y 5m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1053 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month